2X Match My Gift
Make a tax-deductible donation and double your impact to support colorectal cancer patients, survivors, and caregivers.
Chemotherapy is treatment with cytotoxic drugs that are given either intravenously (IV) or by mouth (pills). Cytotoxic drugs are toxic to cancer cells. These drugs travel through the bloodstream and keep cancer cells from growing, dividing, and making more cells.
Because chemotherapy (chemo) travels through the whole body, it can also damage healthy cells. This is why some chemo drugs can cause side effects such as hair loss, mouth sores, and nausea.
Chemotherapy is used to treat both colon and rectal cancer.
The goals of chemotherapy for colorectal cancer depend on the stage and location of the cancer.
Chemotherapy may be given alone or as a part of a treatment plan that includes other types of treatments.
Chemo may be given at different times during treatment, including:
Palliative chemotherapy
Even when cancer is not curable, your doctor may still recommend chemotherapy to improve quality of life. Chemo can sometimes slow the progression of the cancer, relieve cancer-related pain and discomfort, and extend survival.
Because colorectal cancer chemotherapy often damages healthy cells and tissues, side effects are common.
Many patients fear the side effects from treatment more than the cancer itself, but there are some things to keep in mind:
In the past, chemotherapy side effects were a very difficult part of cancer treatment. However, today there are a number of effective ways to manage these with medication and other methods.
Learn how to cope with common chemo side effects:
5-FU and Xeloda are two of the most commonly used chemotherapy drugs for colorectal cancer.
Our Side Effects vs. Symptoms Guidetalks about side effects that are specific If you are being treated with either of these drugs, it’s a good idea to keep this guide handy so you can be informed about their possible side effects.
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Statistics suggested that Christy’s odds of survival were grim, so she leaned into her faith and kept a positive outlook. She tried to control what she could. And, critically, she received biomarker testing.
The EPIC Act would encourage investment in clinical trials for additional uses of existing drugs.